Rela-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience

Journal of the National Cancer Institute

Volumn 94, Issue 11, 2002, Pages 852-854

  Paik, Soonmyung ^a   Bryant, John ^a,b   Tan Chiu, Elizabeth ^a   Romond, Edward ^c   Hiller, William ^a   Park, Kyeongmee ^a   Brown, Ann ^d   Yothers, Greg ^b   Anderson, Steve ^e   Smith, Roy ^a   Wickerham, D Lawrence ^a   Wolmark, Norman ^a  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d NSABP Biostatistical Center   (United States)

^e LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ARTICLE; ASSAY; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; BREAST TUMOR; CLINICAL TRIAL; DIAGNOSTIC ERROR; DRUG CONTRAINDICATION; EVALUATION; GENETICS; HEALTH CARE QUALITY; METABOLISM; METHODOLOGY; PATIENT SELECTION; REPRODUCIBILITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DIAGNOSTIC ERRORS; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PATIENT SELECTION; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0037023986     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.11.852     Document Type: Article

References (16)

1. Firstline, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer a preliminary report
2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
3. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation
4. HER2-a discussion of testing approaches in the USA
5. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer
6. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
7. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
8. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use
9. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
10. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
11. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma
12. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach
13. Standardization in immunohistochemistry
14. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study
15. Reproducibility of LSI HER-2/neu SpectrumOrange and CEP 17 SpectrumGreen Dual Color deoxyribonucleic acid probe kit. For enumeration of gene amplification in paraffin-embedded specimens: A multicenter clinical validation study
16. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH)